Brief: Context Therapeutics Announces Preclinical Data Demonstrating
31/10/2023 13:09
Oct 31 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS ANNOUNCES PRECLINICAL DATA
DEMONSTRATING
DIFFERENTIATED AND ACTIVE PROFILE OF ITS CLAUDIN 6-TARGETED
BISPECIFIC ANTIBODY CTIM-76
* CONTEXT THERAPEUTICS - CTIM-76 EXHIBITS DOSE-PROPORTIONAL
TUMOR
RESPONSES AND SAFETY IN PRECLINICAL MODELS
* CONTEXT THERAPEUTICS - BENCHMARKING STUDIES COMPARING
CTIM-76
WITH CLINICAL-STAGE CLDN6 THERAPIES SUPPORT CTIM-76'S
DIFFERENTIATED PRODUCT PROFILE
* CONTEXT THERAPEUTICS - CTIM-76 IND FILING ON TRACK FOR
LATE Q1
2024
* CONTEXT THERAPEUTICS - LOOK FORWARD TO FILING AN
INVESTIGATIONAL
NEW DRUG APPLICATION LATE IN Q1 OF 2024
Source text for Eikon: ID:nGNX2Lwvmp
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202